The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition

Stephen B. Harrap, Christophe Tzourio, François Cambien, Odette Poirier, Segolene Raoux, John Chalmers, Neil Chapman, Samuel Colman, Solenn Leguennec, Stephen MacMahon, Bruce Neal, Takayoshi Ohkubo, Mark Woodward

Research output: Contribution to journalArticle

Abstract

The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene might have consequences for the risks of vascular diseases. We examined the ACE genotype and the effects of a perindopril-based blood pressure-lowering regimen on macrovascular events, dementia, and cognitive decline among hypertensive and nonhypertensive patients with a history of cerebrovascular disease. ACE I/D genotypes were measured in 5688 of 6105 individuals with previous stroke or transient ischemic attack who participated in the PROGRESS trial. The DD genotype was significantly (P

Original languageEnglish (US)
Pages (from-to)297-303
Number of pages7
JournalHypertension
Volume42
Issue number3
DOIs
Publication statusPublished - Sep 1 2003
Externally publishedYes

    Fingerprint

Keywords

  • Blood pressure
  • Clinical trials
  • Coronary disease
  • Genes
  • Stroke

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Harrap, S. B., Tzourio, C., Cambien, F., Poirier, O., Raoux, S., Chalmers, J., ... Woodward, M. (2003). The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension, 42(3), 297-303. https://doi.org/10.1161/01.HYP.0000088322.85804.96